CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Expert Answers to Clinician Questions

In this podcast episode, listen to Javier Cortes, MD, PhD; Stephen R. D. Johnston, MA, FRCP, PhD; and Sara Tolaney, MD, MPH, as they answer clinician questions from a live webinar covering the latest evidence for individualizing treatment of patients with HR-positive, HER2-negative early breast cancer.